scholarly journals Effects of Chili Treatment on Gastrointestinal and Rectal Sensation in Diarrhea-predominant Irritable Bowel Syndrome: A Randomized, Double-blinded, Crossover Study

2014 ◽  
Vol 20 (3) ◽  
pp. 400-406 ◽  
Author(s):  
Satimai Aniwan ◽  
Sutep Gonlachanvit
Keyword(s):  
Irritable Bowel Syndrome ◽  
Crossover Study ◽  
Rectal Sensation ◽  
Irritable Bowel ◽  
Double Blinded

scholarly journals Effect of herbal extract granules combined with otilonium bromide on irritable bowel syndrome with diarrhoea: a study protocol for a randomised controlled trial

BMJ Open ◽  
2017 ◽  
Vol 7 (11) ◽  
pp. e018362 ◽  
Author(s):  
Joong Il Kim ◽  
Pumsoo Kim ◽  
Jin-Hyun Lee ◽  
Yoo-Jin Kim ◽  
Na-rae Yang ◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Controlled Trial ◽  
Water Extract ◽  
Gastrointestinal Disorder ◽  
Herbal Extract ◽  
Korean Ministry ◽  
Preparation Period ◽  
Irritable Bowel ◽  
Randomised Controlled ◽  
Double Blinded

IntroductionIrritable bowel syndrome (IBS), known as a functional and organic gastrointestinal disorder, is a collection of symptoms that occur together and generally include pain or discomfort in the abdomen and changes in bowel movement patterns. Due to the limitations of conventional treatments, alternative IBS treatments are used by many patients worldwide. Samryungbaekchulsan (SRS), a herbal formula, has long been used for alleviating diarrhoea-predominant IBS (D-IBS) in traditional Korean medicine. Otilonium bromide (OB) is an antimuscarinic compound used to relieve spasmodic pain in the gut, especially in IBS. Although herbal formulae and Western drugs are commonly coadministered for various diseases in Korea, few clinical studies have been conducted regarding the synergic effects of these treatments for any disease, including D-IBS.Methods and analysisThis trial is a randomised, double-blinded, placebo-controlled, double-dummy, four-arm, parallel study. After a 2-week preparation period, 80 patients with D-IBS will be randomly assigned to one of four treatment groups consisting of SRS (water extract granules, 5 g/pack, three times a day) with OB (tablet form, one capsule three times a day) or their placebos, with treatment lasting for 8 weeks. Post-treatment follow-up will be conducted 4 weeks after the end of treatment. The primary outcome is the finding obtained using the Subject’s Global Assessment of Relief method. The secondary outcomes are the severity of symptoms related to D-IBS, determined using a 10-point scale, and the change in symptoms.Ethics and disseminationThis trial has full ethical approval of the Ethics Committee of Catholic Kwandong University International St. Mary’s Hospital (IS15MISV0033) and the Korean Ministry of Food and Drug Safety (30769). The results of the study will be disseminated through a peer-reviewed journal and/or conference presentations.Trial protocol versionIS15MISV0033 version 4.0 (25 July 2016).Trial registration numberKCT0001621(approval date: 10 August 2015).

Melatonin Regulation as a Possible Mechanism for Probiotic (VSL#3) in Irritable Bowel Syndrome: A Randomized Double-Blinded Placebo Study

2014 ◽  
Vol 60 (1) ◽  
pp. 186-194 ◽  
Author(s):  
Reuben K. Wong ◽  
Cao Yang ◽  
Guang-Hui Song ◽  
Jennie Wong ◽  
Khek-Yu Ho
Keyword(s):  
Irritable Bowel Syndrome ◽  
Irritable Bowel ◽  
Double Blinded

scholarly journals Is bran efficacious in irritable bowel syndrome? A double blind placebo controlled crossover study.

Gut ◽  
1987 ◽  
Vol 28 (2) ◽  
pp. 221-225 ◽  
Author(s):  
M R Lucey ◽  
M L Clark ◽  
J Lowndes ◽  
A M Dawson
Keyword(s):  
Irritable Bowel Syndrome ◽  
Crossover Study ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Irritable Bowel

scholarly journals A Literature Review of Dietary Habits, Defecation Habits and Skill Care to Prevent Fecal Incontinence in Elderly Individuals with Irritable Bowel Syndrome

2020 ◽  
Author(s):  
Yohei Okawa
Keyword(s):  
Irritable Bowel Syndrome ◽  
Fecal Incontinence ◽  
Dietary Habits ◽  
Negative Impact ◽  
Rectal Sensation ◽  
Significant Negative Impact ◽  
Tract Disease ◽  
Irritable Bowel ◽  
Diet And Lifestyle

The irritable bowel syndrome (IBS) is functional gastrointestinal tract disease, include abnormal defecation and abdominal pain. The Rome IV criteria define fecal incontinence as "recurrent and uncontrolled stool leakage that lasts more than 3 months." Fecal incontinence is common in patients with IBS and can have a significant negative impact on daily life and reduce the patient's quality of life. Diet and lifestyle guidance are needed to prevent fecal incontinence. Fecal incontinence can be reduced by ingesting dietary fiber, which can improve stool properties, and avoiding foods with stool-softening properties. Additionally, defecation habit guidance is important for preventing fecal incontinence. If rectal sensation is normal, it is recommended to go to the bathroom as soon as there is a desire to defecate. In elderly people, if there is stool in the rectum due to decreased rectal sensation and it continues to accumulate in the rectum without triggering the urge to defecate, overflowing leaky fecal incontinence may occur. For such patients, defecation habit training teaching them to defecate even if they do not have the desire to defecate may be effective. Education and advice on defecation reduces fecal incontinence and is beneficial to caregivers.

scholarly journals Symptomatic improvement with gluten restriction in irritable bowel syndrome: a prospective, randomized, double blinded placebo controlled trial

2016 ◽  
Vol 14 (4) ◽  
pp. 343 ◽  
Author(s):  
Vinay G Zanwar ◽  
Sunil V Pawar ◽  
Pravir A Gambhire ◽  
Samit S Jain ◽  
Ravindra G Surude ◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Controlled Trial ◽  
Symptomatic Improvement ◽  
Irritable Bowel ◽  
Double Blinded

scholarly journals FODMAPs, but Not Gluten, Affect Symptoms and the Fecal Environment in Subjects With Irritable Bowel Syndrome. A Double Blinded-Randomized Three-Way Crossover Study

2021 ◽  
Vol 5 (Supplement_2) ◽  
pp. 601-601
Author(s):  
Elise Nordin ◽  
Carl Brunius ◽  
Johan Dicksved ◽  
Erik Pelve ◽  
Rikard Landberg ◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Gut Microbiota ◽  
Rrna Gene ◽  
Microbiota Composition ◽  
Double Blind ◽  
Funding Sources ◽  
Irritable Bowel ◽  
Double Blinded ◽  
Gut Microbiota Composition ◽  
Modest Effect

Abstract Objectives Irritable bowel syndrome (IBS) symptoms have been associated with fermentable oligo-, di-, monosaccharides and polyols (FODMAPs) as well as gluten. We aimed to evaluate the effects of provocations with diets rich in such components on IBS symptoms. We further aimed to study effects of FODMAPs and gluten on microbiota and if the microbiota composition was related to the severity of IBS symptoms. Methods A double-blind, placebo-controlled, randomised three-way crossover design (n = 110) was conducted. From run-in and throughout the study, IBS subjects maintained a diet with minimal FODMAP content and no gluten. Participants were block-randomised to one-week interventions with FODMAPs (50 g/day), gluten (17.3 g/day) or placebo, separated by one week of wash-out. Fecal samples were collected after each study week and analyzed for gut microbiota composition by sequencing of 16S rRNA gene amplicons. IBS symptoms were monitored by the IBS severity scoring system (IBS-SSS). Results In subjects with moderate to severe IBS (n = 103), FODMAPs caused higher total IBS-SSS (mean [SE] = 240 [9]) than placebo (208 [9]; p = 0.00056) or gluten (198 [9]; p = 0.013), but with no difference between gluten and placebo (p = 1.0). Relative abundance of Anaerostipes, Bifidobacterium and Faecalibacterium were higher after FODMAP compared to placebo. We found no difference in gut microbiota composition between gluten and placebo and no significant correlations between genera and severity of IBS-SSS. Conclusions In subjects with IBS, FODMAPs had an adverse but modest effect on typical IBS symptoms, whereas gluten had no effect. The microbiota composition was affected by the FODMAP but not the gluten intervention, in comparison to placebo. None of these differences were correlated to the severity of symptoms reflected in IBS-SSS, suggesting no apparent link between gut microbiota composition and IBS symptoms following intervention. Funding Sources Formas and the Swedish Research Council.

Sign in / Sign up

Export Citation Format

Share Document